Linsenn

Linsenn is a clinical-stage biotechnology company based in Suzhou, China, specializing in the research and development of mRNA-based vaccines and therapeutics. The company has established a robust technology platform encompassing mRNA sequence optimization and proprietary lipid nanoparticle (LNP) delivery systems. Linsenn's primary focus is on addressing unmet needs in infectious diseases, with its lead mRNA COVID-19 vaccine candidate, LS-001, currently in clinical trials. Beyond vaccines, the company is expanding its platform to develop personalized cancer immunotherapies and other protein replacement therapies. Linsenn aims to leverage the speed and flexibility of mRNA technology to provide effective medical solutions for global health challenges.